Persica Pharmaceuticals Limited

Persica Pharmaceuticals Limited is a small, active company based in Canterbury, UK, established eleven years ago in 2013. It employs seven people and holds assets of £2,275,929. The company has a real registered address and is overseen by four directors, although no owners are officially listed. Persica Pharmaceuticals is an irregular importer, primarily dealing in machinery, boilers, and mechanical appliances – parts, with its last import operation recorded over five years ago in January 2018.

The company operates within the "other business support service activities n.e.c." industries and is currently undergoing a period of transformation, focused on developing a groundbreaking treatment for chronic Low Back Pain with Modic changes. Its website details a clinical-stage biotechnology approach, centered around PP353, a patented antibiotic injection designed to target the site of infection directly. The company's therapeutic focus is on addressing a significant unmet need, offering a non-opioid treatment option for a condition affecting millions.

Financially, Persica Pharmaceuticals shows a concerning trend. Current assets have fallen by 24%, dropping to £2,300,000, while net assets have plummeted 30% to £2,000,000. Cash reserves have also declined significantly, falling 30% to £2,200,000. Creditors have increased substantially, rising 70% to £320,000, and other taxation social security payable has increased by 57% to £68,000. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) allows for agility, but the decrease in equity suggests a need for careful financial management. The accounts are unaudited, likely due to the company’s small size, and no auditor is mentioned. The company’s reliance on the continuing support of the directors is also noted.

Registered in England/Wales under the registration number 08697526, with a registered address at CT4 6HD, Canterbury, Kent, 7 Denne Hill Business Centre, Womenswold.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.